Associated Papers
Distinct characteristics of VEXAS-causative UBA1 M41 and recurrent functional non-M41 mutations.
Sakuma M et al.
Leukemia, 2025
Efficacy and safety of targeted therapies in VEXAS syndrome: retrospective study from the FRENVEX.
Hadjadj J et al.
Annals of the Rheumatic Diseases, 2024
Select a paper to view details